IRI Separation Technologies Inc.: Agreement with Japanese Partners to Produce Helicobacter Pylori and Avian Influenza Specific A

IRI (TSX VENTURE:IRI), is pleased to announce it has signed a Letter of Intent
with PharmaFoods International of Kyoto, Japan, to use their Vaccine to produce
Helicobacter Pylori antibodies to service their existing market and to jointly
develop and market an Avian Influenza specific antibody. The Letter of Intent
also includes Sceti K.K. as a partner to market and distribute IRI products in
Japan. Sceti K.K. provides market entry for foreign companies that offer
innovative solutions to problems in the fields of medical diagnostic and
industrial manufacturing.


PharmaFoods International Co. Ltd (PFI) is a leading Venture company in Japan
and markets a variety of IgY antibody products. PFI proposes to supply IRI with
their H. Pylori vaccine from which IRI will produce a 50% pure specific antibody
product targeted at the H. Pylori bacteria. PFI hopes to expand its market by
introducing the IRI Product, which has a higher assay than is currently
available.


H. Pylori bacteria are responsible for the symptoms associated with stomach
ulcers and can be controlled with H. Pylori antibodies. It has been estimated
that a majority of Asians and Mexicans suffer from the HP bacteria. Although
antibiotics are currently prescribed for such conditions there is a 15% failure
with antibiotics and similar re-infection.


IRI has been carrying out research with H. Pylori antibodies and has been
supplying such product to some 30 H. Pylori patients over the past three years.
By working with PFI and servicing their existing market, IRI expects to have
product on the Asian Market in 2009.


Avian Influenza (H5N1) is considered by the World Health Organization as
possibly the next Pandemic to hit the human population. There have been several
incidents in Asia and death occurs with days of the virus being contracted.
Although human vaccines have been approved it takes the human immune system over
three weeks to develop the required antibodies to combat the virus infection.
Preliminary research carried out by the Canadian Department of Defense has shown
in animal studies, that inhalation of the H5N2 Avian influenza antibodies gives
immediate protection against the virus. There is also some evidence that it will
give protection against other H5 flu related viruses.


PharmaFoods International Co. Ltd., in collaboration with Sceti K.K. have stated
that they wish to work with IRI in the validation and marketing of the Avian
Influenza antibodies and IRI will arrange to secure the required eggs from H5N2
vaccinated chickens. The delivery system proposed by the Japanese group is such
that prolonged clinical trials will not be required.


To enable IRI to perform the terms of the Japanese agreement:

IRI is currently negotiating with creditors to restructure existing debt and
effect a sale of certain egg breaking assets, not required in the antibody
extraction process, for cash and other consideration:


As part of the restructuring, the resignation of David Mason has been accepted
as a Director, although David will continue as the Chief Operation Officer.
(COO). The Company is also negotiating the cancelling of all options to company
employees and contractors. A lawsuit relating to the supply of $150,000.00 of
shell eggs to the egg breaking facility over the four week period prior to the
closure of the facility has been issued against a subsidiary of IRI which we
anticipate will be resolved during the restructuring.


IRI is considering two proposals relative to the takeover of the Sales and
Marketing operations, such proposals include the injection of working capital
into the IRI operations.


IRI advises that it has been unable to update its website. For the most recent
information please see the Company's filings on SEDAR. IRI's website will be
updated upon completion of restructuring.


About IRI Separation Technologies Inc.

IRI Separation Technologies Inc. (TSX VENTURE:IRI) is a biotechnology company
that specializes in the extraction development and commercialization of
monoclonal and polyclonal immunoglobulin antibodies for virus and bacteria
related health issues. Intended for use as a Neutracuitical for human
consumption, the antibodies are derived from bovine whey and chicken eggs. The
immunoglobulin antibodies are intended for both the general and specific
antibody market.


Submitted on behalf of the Board of Directors of IRI

Forward Looking Statements: The above contains forward looking statements that
are subject to a number of known and unknown risks, uncertainties and other
factors that may cause actual results to differ materially from those
anticipated in our forward looking statements. Factors that could cause such
differences include: changes in world markets for Neutracuiticals, equity market
conditions, costs and supply of materials relevant to the Neutracuitical
industry, change in government and changes to regulations affecting the
Neutracuitical industry. Forward-looking statements in this release include
statements and the potential financing. Although we believe the expectations
reflected in our forward looking statements are reasonable, results may vary,
and we cannot guarantee future results, levels of activity, performance or
achievements.
IEMR Resources (TSXV:IRI)
Graphique Historique de l'Action
De Mai 2024 à Juin 2024